Document is current
Any future updates will be listed below
-
Authors
Kurpińska, Anna https://orcid.org/0000-0003-2130-0099
Suraj-Prażmowska, Joanna https://orcid.org/0000-0002-0190-2474
Stojak, Marta https://orcid.org/0000-0003-2291-4068
Jarosz, Joanna https://orcid.org/0000-0002-9287-6207
Mateuszuk, Łukasz https://orcid.org/0000-0001-8234-3346
Niedzielska-Andres, Ewa https://orcid.org/0000-0001-7310-1556
Smolik, Magdalena https://orcid.org/0000-0003-1619-0913
Wietrzyk, Joanna https://orcid.org/0000-0003-4980-6606
Kalvins, Ivars https://orcid.org/0000-0001-6076-7818
Walczak, Maria https://orcid.org/0000-0002-5670-9866
Chłopicki, Stefan https://orcid.org/0000-0002-2878-3858
-
Funding
Funding for this research was provided by:
Latvian National Fundamental and Applied Research (lzp-2018/1-0143)
Narodowe Centrum Badań i Rozwoju (STRATEGMED1/233226/11/NCBR/2015)
- License Information
-
More Information
Article History
Received: 20 January 2022
Accepted: 9 June 2022
First Online: 20 June 2022
Declarations
:
: Not applicable.
: Not applicable.
: A conflict of interest disclosure statement: SCH, IK, MS, JW have filed a patent on aromatic sulfonamides derivatives that inhibits PDIA1 (WO/2021/141506) and PDIA3 (WO/2021/141507). Other authors declare no conflict of interest.
